Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2011

01-02-2011 | Review

The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus

Authors: J Michelle Kahlenberg, Mariana J Kaplan

Published in: Arthritis Research & Therapy | Issue 1/2011

Login to get access

Abstract

Patients with systemic lupus erythematosus have up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease. Recent advances in the etiology of vascular damage in this disease stress the interplay of lupus-specific inflammatory factors with traditional cardiac risk factors, leading to increased endothelial damage. This review analyzes the putative role that immune dysregulation and lupus-specific factors may play in the pathogenesis of premature vascular damage in this disease. The potential role of various cytokines, in particular type I interferons, in the development of accelerated atherosclerosis is examined. Potential therapeutic targets are discussed.
Appendix
Available only for authorised users
Literature
1.
Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976, 60: 221-225. 10.1016/0002-9343(76)90431-9.PubMed
2.
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, D'Agostino RB, Kuller LH: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997, 145: 408-415.PubMed
3.
Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH: Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis Rheum. 2009, 61: 1396-1402. 10.1002/art.24537.PubMedCentralPubMed
4.
Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I.PubMed
5.
Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE: Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007, 56: 3412-3419. 10.1002/art.22924.PubMed
6.
Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ: Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004, 103: 3677-3683. 10.1182/blood-2003-09-3198.PubMed
7.
El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, Bernstein RM, Bruce IN: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004, 110: 399-404. 10.1161/01.CIR.0000136807.78534.50.PubMed
8.
Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999, 42: 51-60. 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D.PubMed
9.
Roldan C, Joson J, Sharrar J, Qualls C, Sibbitt W: Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study. J Rheumatol. 2010, 37: 71-78. 10.3899/jrheum.090665.PubMedCentralPubMed
10.
Kiani AN, Vogel-Claussen J, Magder LS, Petri M: Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol. 2010, 37: 579-584. 10.3899/jrheum.090824.PubMed
11.
Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG: Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009, 30: 1837-1843. 10.1093/eurheartj/ehp205.PubMed
12.
Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, Schwartz JE, Sammaritano L, Levine DM, Salmon JE: Systemic lupus erythematosus predicts increased left ventricular mass. Circulation. 2007, 116: 419-426. 10.1161/CIRCULATIONAHA.106.673319.PubMed
13.
Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352: 1685-1695. 10.1056/NEJMra043430.PubMed
14.
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010, 464: 1357-1361. 10.1038/nature08938.PubMedCentralPubMed
15.
Lindner V, Fingerle J, Reidy MA: Mouse model of arterial injury. Circ Res. 1993, 73: 792-796.PubMed
16.
Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000, 101: 841-843.PubMed
17.
Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A: Endothelial microparticles in diseases. Cell Tissue Res. 2009, 335: 143-151. 10.1007/s00441-008-0710-9.PubMed
18.
Briasoulis A, Tousoulis D, Antoniades C, Stefanadis C, Papageorgiou N: The role of endothelial progenitor cells in vascular repair after arterial injury and atherosclerotic plaque development. Cardiovasc Ther. 2010,
19.
Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005, 111: 2981-2987. 10.1161/CIRCULATIONAHA.104.504340.PubMed
20.
George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, Michowitz Y, Miller H, Keren G: Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol. 2003, 23: e57-60. 10.1161/01.ATV.0000107029.65274.db.PubMed
21.
Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001, 89: E1-E7. 10.1161/hh1301.093953.PubMed
22.
MacEneaney OJ, Kushner EJ, Westby CM, Cech JN, Greiner JJ, Stauffer BL, DeSouza CA: Endothelial progenitor cell function, apoptosis, and telomere length in overweight/obese humans. Obesity. 2010, 18: 1677-1682. 10.1038/oby.2009.494.PubMed
23.
Zhang Y, Herbert BS, Rajashekhar G, Ingram DA, Yoder MC, Clauss M, Rehman J: Premature senescence of highly proliferative endothelial progenitor cells is induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein kinase pathway. FASEB J. 2009, 23: 1358-1365. 10.1096/fj.08-110296.PubMedCentralPubMed
24.
Brunetti ND, Munno I, Pellegrino PL, Ruggero V, Correale M, De Gennaro L, Cuculo A, Campanale EG, Di Biase M: Inflammatory cytokines imbalance in the very early phase of acute coronary syndrome: correlations with angiographic findings and in-hospital events. Inflammation. 2011, 34: 58-66. 10.1007/s10753-010-9208-1.PubMed
25.
Reynolds HR, Buyon J, Kim M, Rivera TL, Izmirly P, Tunick P, Clancy RM: Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis. 2010, 210: 569-574. 10.1016/j.atherosclerosis.2009.12.007.PubMedCentralPubMed
26.
Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T, Shintani A, Stein CM: Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008, 35: 1789-1794.PubMedCentralPubMed
27.
Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC: Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis. 2007, 66: 865-870. 10.1136/ard.2006.065631.PubMedCentralPubMed
28.
Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ: Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007, 110: 2907-2915. 10.1182/blood-2007-05-089086.PubMedCentralPubMed
29.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.PubMedCentralPubMed
30.
Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T: Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987, 70: 562-569.PubMedCentralPubMed
31.
Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB: Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol. 2009, 182: 34-38.PubMedCentralPubMed
32.
Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ: The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol. 2010, 185: 4457-4469. 10.4049/jimmunol.1001782.PubMedCentralPubMed
33.
Thacker SG, Duquaine D, Park J, Kaplan MJ: Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus. 2010, 19: 288-299. 10.1177/0961203309353773.PubMedCentralPubMed
34.
Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS: Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007, 56: 3759-3769. 10.1002/art.23035.PubMed
35.
Zhao W, Somers E, McCune WJ, Kaplan MJ: Type I Interferon signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2009, 59: S582-
36.
Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ: The detrimental effects of IFN-{alpha} on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol. 2010, 185: 4457-4469. 10.4049/jimmunol.1001782.PubMedCentralPubMed
37.
Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, McCune WJ, Kaplan MJ: A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010, 184: 3284-3297. 10.4049/jimmunol.0902199.PubMedCentralPubMed
38.
Hacbarth E, Kajdacsy-Balla A: Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum. 1986, 29: 1334-1342. 10.1002/art.1780291105.PubMed
39.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003, 197: 711-723. 10.1084/jem.20021553.PubMedCentralPubMed
40.
Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM: Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation. 2007, 116: 2043-2052. 10.1161/CIRCULATIONAHA.107.697789.PubMed
41.
Niessner A, Weyand CM: Dendritic cells in atherosclerotic disease. Clin Immunol. 2010, 134: 25-32. 10.1016/j.clim.2009.05.006.PubMedCentralPubMed
42.
Enocsson H, Sjöwall C, Skogh T, Eloranta ML, Rönnblom L, Wetterö J: Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?. Arthritis Rheum. 2009, 60: 3755-3760. 10.1002/art.25042.PubMed
43.
Nikpour M, Gladman DD, Ibaez D, Urowitz MB: Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus. 2009, 18: 966-973. 10.1177/0961203309105130.PubMed
44.
McMahon M, Hahn BH: Atherosclerosis and systemic lupus erythematosus - mechanistic basis of the association. Curr Opin Immunol. 2007, 19: 633-639. 10.1016/j.coi.2007.11.001.PubMedCentralPubMed
45.
Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J: TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003, 12: 454-461. 10.1191/0961203303lu412oa.PubMed
46.
Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J: Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol. 2008, 37: 352-359. 10.1080/03009740802007514.PubMed
47.
Major AS, Singh RR, Joyce S, Van Kaer L: The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res. 2006, 34: 49-66. 10.1385/IR:34:1:49.PubMedCentralPubMed
48.
Becker-Merok A, Eilertsen GØ, Nossent JC: Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease. J Rheumatol. 2010, 37: 2039-2045. 10.3899/jrheum.100180.PubMed
49.
van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J: Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009, 388: 261-265. 10.1016/j.bbrc.2009.07.152.PubMed
50.
Mok MY, Wu HJ, Lo Y, Lau CS: The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol. 2010, 37: 2046-2052. 10.3899/jrheum.100293.PubMed
51.
Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L, Li M: Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 1472-1483. 10.1002/art.24499.PubMed
52.
Chung CP, Long AG, Solus JF, Rho YH, Oeser A, Raggi P, Stein CM: Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009, 18: 799-806. 10.1177/0961203309103582.PubMedCentralPubMed
53.
Clancy R, Ginzler E: Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010, 36: 145-160. 10.1016/j.rdc.2009.12.011.PubMed
54.
Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR: The peroxisome proliferator-activated receptor {gamma} agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol. 2009, 182: 340-346.PubMedCentralPubMed
55.
Braun N, Wade N, Wakeland E, Major A: Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus- susceptible LDLr-/- mice. Lupus. 2008, 17: 1070-1078. 10.1177/0961203308093551.PubMedCentralPubMed
56.
Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC: The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol. 2002, 169: 6020-6029.PubMed
57.
Al-Lamki R, Bradley J, Pober J: Endothelial cells in allograft rejection. Transplantation. 2008, 86: 1340-1348. 10.1097/TP.0b013e3181891d8b.PubMedCentralPubMed
58.
Bonelli M, Smolen JS, Scheinecker C: Treg and lupus. Ann Rheum Dis. 2010, 69: i65-i66. 10.1136/ard.2009.117135.PubMed
59.
Nilsson J, Wigren M, Shah P: Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis. Trends Cardiovasc Med. 2009, 19: 272-276. 10.1016/j.tcm.2010.02.010.PubMed
60.
Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X: Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res. 2009, 104: 550-558. 10.1161/CIRCRESAHA.108.191361.PubMedCentralPubMed
61.
Clancy RM: Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep. 2000, 2: 39-43. 10.1007/s11926-996-0067-6.PubMed
62.
Bassi N, Zampieri S, Ghirardello A, Tonon M, Zen M, Beggio S, Matsuura E, Doria A: Oxldl/2gpi complex and anti-oxldl/2gpi In Sle: prevalence and correlates. Autoimmunity. 2009, 42: 289-291. 10.1080/08916930902828247.PubMed
63.
Fraser DA, Tenner AJ: Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol. 2010, 185: 3932-3939. 10.4049/jimmunol.1002080.PubMedCentralPubMed
64.
Haskard DO, Boyle JJ, Mason JC: The role of complement in atherosclerosis. Curr Opin Lipidol. 2008, 19: 478-482. 10.1097/MOL.0b013e32830f4a06.PubMed
65.
Mayadas TN, Tsokos GC, Tsuboi N: Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009, 120: 2012-2024. 10.1161/CIRCULATIONAHA.108.771170.PubMedCentralPubMed
66.
Borba EF, Bonf E, Vinagre CG, Ramires JA, Maranho RC: Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000, 43: 1033-1040. 10.1002/1529-0131(200005)43:5<1033::AID-ANR11>3.0.CO;2-B.PubMed
67.
McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH: Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 2428-2437. 10.1002/art.24677.PubMedCentralPubMed
68.
Hahn BH, Lourencço EV, McMahon M, Skaggs B, Le E, Anderson M, Iikuni N, Lai CK, La Cava A: Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin. Lupus. 2010, 19: 913-917. 10.1177/0961203310364397.PubMedCentralPubMed
69.
Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF: Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum. 2010, 62: 2064-2072.PubMedCentralPubMed
70.
Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V: Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus. 2002, 11: 208-214. 10.1191/0961203302lu165oa.PubMed
71.
Kiani AN, Magder L, Petri M: Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol. 2008, 35: 1300-1306.PubMed
72.
Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA: Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 2002, 46: 2686-2694. 10.1002/art.10542.PubMed
73.
George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y: Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999, 99: 2227-2230.PubMed
74.
Baron MA, Khamashta MA, Hughes GRV, D'Cruz DP: Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheuma Dis. 2005, 64: 144-146. 10.1136/ard.2003.016204.
75.
Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, Facco M, Guglielmini G, Boscaro E, Mezzasoma AM, Momi S, Pengo V: Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009, 123: 444-451. 10.1016/j.thromres.2008.05.015.PubMed
76.
Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE: Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006, 54: 3918-3925. 10.1002/art.22265.PubMed
77.
Sacré K, Brihaye B, Hyafil F, Serfaty JM, Escoubet B, Zennaro MC, Lidove O, Laissy JP, Papo T: Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum. 2010, 62: 2093-2100. 10.1002/art.27304.PubMed
78.
O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L, March LM, Latchman DS, Isenberg DA, Rahman A: Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 845-854. 10.1002/art.27286.PubMed
79.
Rodrigues CEM, Bonfá E, Carvalho JF: Review on anti-lipoprotein lipase antibodies. Clin Chimi Acta. 2010, 411: 1603-1605. 10.1016/j.cca.2010.07.028.
80.
Domiciano D, Carvalho J, Shoenfeld Y: Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. Lupus. 2009, 18: 1233-1238. 10.1177/0961203309346654.PubMed
81.
Duval A, Helley D, Capron L, Youinou P, Renaudineau Y, Dubucquoi S, Fischer AM, Hachulla E: Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology. 2010, 49: 1049-1055. 10.1093/rheumatology/keq041.PubMed
82.
Elliott J, Manzi S: Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2009, 23: 481-494. 10.1016/j.berh.2009.03.005.PubMed
83.
Meyer O: Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine. 2010, 77: 384-389. 10.1016/j.jbspin.2010.04.010.PubMed
84.
George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y: Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus. 1999, 8: 220-226. 10.1191/096120399678847597.PubMed
85.
Mandal K, Foteinos G, Jahangiri M, Xu Q: Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus. 2005, 14: 742-746. 10.1191/0961203305lu2212oa.PubMed
86.
Petri M: Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996, 5 (Suppl 1): S16-22. 10.1177/096120339600500105.PubMed
87.
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2399-2406. 10.1056/NEJMoa035471.PubMed
88.
Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S: Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001, 37: 1075-1082.PubMed
89.
Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2407-2415. 10.1056/NEJMoa035611.PubMed
90.
Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, Brenol JC, Chacón-Diaz R, Neira OJ, Berbotto GA, De La Torre IG, Acevedo-Vázquez EM, Massardo L, Barile-Fabris LA, Caeiro F, Silveira LH, Sato EI, Buliubasich S, Alarcón GS, Pons-Estel BA, Grupo Latino Americano de Estudio del Lupus Eritematoso (Gladel): Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010, 62: 855-862. 10.1002/art.27300.PubMed
91.
Kalia S, Dutz JP: New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007, 20: 160-174. 10.1111/j.1529-8019.2007.00131.x.PubMed
92.
Gibson WT, Hayden MR: Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci. 2007, 1110: 209-221. 10.1196/annals.1423.023.PubMed
93.
van Leuven SI, van Wijk DF, Volger OL, de Vries JP, van der Loos CM, de Kleijn DV, Horrevoets AJ, Tak PP, van der Wal AC, de Boer OJ, Pasterkamp G, Hayden MR, Kastelein JJ, Stroes ES: Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis. 2010, 211: 231-236. 10.1016/j.atherosclerosis.2010.01.043.PubMed
94.
Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM, Wong CK, Lun SW, Ko GT, Lam CW, Lam CS: Metabolic syndrome, endothelial injury, and subclinical Page 10 of 10 atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010, 39: 42-49. 10.3109/03009740903046668.PubMed
95.
Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010, 69: 1269-1274. 10.1136/ard.2009.117200.PubMedCentralPubMed
96.
Wajed J, Ahmad Y, Durrington PN, Bruce IN: Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology. 2004, 43: 7-12. 10.1093/rheumatology/keg436.PubMed
97.
Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato EI: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology. 2007, 46: 1560-1565. 10.1093/rheumatology/kem186.PubMed
98.
Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001, 108: 391-397.PubMedCentralPubMed
99.
Petri M: Lupus Atherosclerosis Prevention Study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum. 2006, 54: S520-
100.
Sandborg CI, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gittelman M, Wallace CA, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed A, Tegler C, APPLE Investigators: Does atorvastatin reduce progression of carotid intimal medial thickening in childhood SLE? Results from the Atherosclerosis Prevention in Pediatric Lupus (APPLE) trial: a multicenter, randomized, double-blind placebo-controlled study [abstract]. Arthritis Rheum. 2010, 62: S1677-
101.
Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K: Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol. 2006, 177: 3028-3034.PubMedCentralPubMed
102.
Amuro H, Ito T, Miyamoto R, Sugimoto H, Torii Y, Son Y, Nakamichi N, Yamazaki C, Hoshino K, Kaisho T, Ozaki Y, Inaba M, Amakawa R, Fukuhara S: Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum. 2010, 62: 2073-2085.PubMed
103.
Lin BF, Jeng SJ, Chiang BL, Huang CC: Dietary fat affects lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr. 1997, 77: 657-669. 10.1079/BJN19970063.PubMed
Metadata
Title
The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus
Authors
J Michelle Kahlenberg
Mariana J Kaplan
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3264

Other articles of this Issue 1/2011

Arthritis Research & Therapy 1/2011 Go to the issue

Review

In vivoapproaches to investigate ANCA-associated vasculitis: lessons and limitations

Research article

Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis

Research article

Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway

Research article

Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+Th/Treg cell subset imbalance in ankylosing spondylitis

Research article

Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus

Research article

Modulation of transforming growth factor beta signalling pathway genes by transforming growth factor beta in human osteoarthritic chondrocytes: involvement of Sp1 in both early and late response cells to transforming growth factor beta
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits